Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

Inclusion Criteria: * Histopathologically confirmed rectal adenocarcinoma: All other histological types are excluded. The patients have concurrent hemorrhoids documented by colonoscopy report or clinical physical examination. * Clinical Pathological Stage: Tumor staged as T3-4 or N+, M0 (according to the AJCC （American Joint Committee on Cancer）TNM （Tumor-Node-Metastasis) Staging System, 9th Edition; see Appendix 1). * Biomarker Status: Immunohistochemical staining of the tissue specimen demonstrates high expression of YWHAB in rectal cancer. * Age: 18 to 75 years old, inclusive, at the time of signing the Informed Consent Form (ICF). * Performance Status: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (see Appendix 3). * Prior Therapy: No prior systemic anti-tumor therapy for rectal cancer, including cytotoxic chemotherapy, immune checkpoint inhibitor therapy, molecular targeted therapy, endocrine therapy, etc. * Adequate Organ Function: Based on laboratory values obtained during the screening period:White Blood Cell (WBC) count ≥ 3.0 × 10⁹/L, absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L, platelet count ≥ 75 × 10⁹/L, serum Total Bilirubin ≤ 1.5 × Upper Normal Limit (UNL), aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≤ 2.5 × UNL, serum Creatinine ≤ 1.5 × UNL. * Contraception (Females of Childbearing Potential - FCBP): FCBP must have a negative serum pregnancy test within 3 days prior to initiation of study treatment. They must be willing to use a medically approved highly effective method of contraception (e.g., intrauterine device, oral contraceptives, condoms) during the study period and for 3 months after the last dose of study drug. * Contraception (Males): Male subjects with partners of childbearing potential must use effective methods of contraception during the study period and for 3 months after the last dose of study drug. * Consent and Compliance: The subject has voluntarily agreed to participate by signing the ICF and is willing and able to comply with scheduled visits, study treatment, laboratory tests, and other trial procedures. Exclusion Criteria: * Distant Metastasis: Confirmed by systemic imaging (CT（Computed Tomography）, MR （Magnetic Resonance Imaging）, or PET-CT （Positron Emission Tomography - Computed Tomography）) encompassing at least the chest, abdomen, and pelvis. * Pharmacogenetic Deficiency: Known complete DPD (dihydropyrimidine dehydrogenase) enzyme deficiency or homozygous UGT1A1\*28 (7/7) genotype identified by whole-genome testing. * Acute Surgical Complications: Presence of complete intestinal obstruction, active bleeding, or perforation requiring emergency surgery. * Other Active Malignancies: History or concurrent presence of other active malignancies, except for malignancies treated with curative intent with no recurrence for \>5 years, or adequately treated carcinoma in situ (e.g., cervical carcinoma in situ, non-melanoma skin cancer). * Thromboembolic Events: History of thromboembolic events (e.g., cerebrovascular accident \[including transient ischemic attack\], pulmonary embolism, deep vein thrombosis) within 12 months prior to study enrollment. * Significant Cardiac Disease: Occurrence of any of the following within 12 months prior to enrollment: myocardial infarction, severe/unstable angina, heart failure of NYHA （New York Heart Association Functional Classification）class 2 or higher, clinically significant supraventricular or ventricular arrhythmia requiring treatment, or symptomatic congestive heart failure. * Recent Infection/Fever: Systemic antibiotic use for ≥7 days within 4 weeks prior to enrollment, or unexplained fever \>38.5°C during screening or prior to the first dose (fever attributed to the tumor by the investigator is allowed). * Major Surgery/Trauma: Undergone major surgery (e.g., laparotomy, thoracotomy, organ resection via laparoscopy) or experienced significant trauma within 2 months prior to enrollment. The surgical incision must be fully healed before study entry. * HIV/AIDS: Known HIV (Human Immunodeficiency Virus) infection or AIDS (Acquired Immunodeficiency Syndrome)-related illness. * Significant Pulmonary/Systemic Disease: Presence of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases (e.g., diabetes mellitus, hypertension, pulmonary fibrosis, acute pneumonitis). * Untreated Active Hepatitis: Untreated active hepatitis B virus (defined as HBV-DNA ≥ 500 IU/mL) or hepatitis C virus (defined as HCV-RNA above the lower limit of quantification), or known co-infection with HBV and HCV. * Drug Hypersensitivity: Known or suspected history of hypersensitivity to any of the drugs related to the study treatment. * Investigator Discretion: Any other condition that, in the judgment of the investigator, would make the patient unsuitable for participation in the study.